Real-world effectiveness and safety of first-line lorlatinib in ALK-positive advanced NSCLC: Updated interim analysis from India (ESMO Asia 2026) - Oct 1, 2026 - Abstract #995P; Pres time: Dec 4, 2026; 05:15 PM - 06:15 PM; Location: Poster area (Exhibition); No abstract available
Clinical • Metastases • Real-world • Real-world effectiveness • Real-world evidence • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK
|
|
Ullas Batra; Somnath Roy; Nandini S. Menon; Narayanan K. Warrier; Akhil Kapoor; Chandragouda Dodagoudar; Senthil Rajappa; Raja Thirumalairaj; Suresh Advani; Harish Thanusubramanian; Akshata S. Mane
|